key: cord-1000706-eudwzib4 authors: Saketkoo LA, Lesley Ann; Jensen, Kelly; Nikoletou, Dimitra; Newton, Jacqui J.; Rivera, Frank J.; Howie, Mike; Reese, Rodney K.; Goodman, Melanie; Hart, Patricia B.; Bembry, Whitney; Russell, Adam; Lian, Isabelle; Lammi, Matthew R.; Scholand MB, Mary Beth; Russell AM, Anne-Marie title: Sarcoidosis Illuminations on Living During COVID-19: Patient Experiences of Diagnosis, Management, and Survival Before and During the Pandemic * date: 2022-03-24 journal: J Patient Exp DOI: 10.1177/23743735221075556 sha: b2fa02cc5c0bc9a29fd045f3667da4bf0f02e601 doc_id: 1000706 cord_uid: eudwzib4 Background: Inspired by intense challenges encountered by patients and clinicians, we examined the experiences of living with sarcoidosis in three of the hardest impacted English-speaking cities during the early COVID-19 pandemic: London, New Orleans, and New York. Methods: A multi-disciplinary, multi-national research team including 6 patient leaders conducted qualitative investigations with analyses rooted in grounded theory. Recruitment occurred by self-referral through patient advocacy groups. Results: A total of 28 people living with sarcoidosis participated. The majority of patients had multi-system and severe sarcoidosis. Dominant themes were consistent across groups with differences expressed in spirituality and government and health systems. Racial, gender, and able-bodied inequity were voiced regarding healthcare access and intervention, societal interactions, and COVID-19 exposure and contraction. Agreement regarding extreme disruption in care and communication created concern for disability and survival. Concerns of COVID-19 exposure triggering new sarcoidosis cases or exacerbating established sarcoidosis were expressed. Pre-COVID-19 impediments in sarcoidosis healthcare delivery, medical knowledge, and societal burdens were intensified during the pandemic. Conversely, living with sarcoidosis cultivated personal and operational preparedness for navigating the practicalities and uncertainties of the pandemic. Optimism prevailed that knowledge of sarcoidosis, respiratory, and multi-organ diseases could provide pathways for COVID-19-related therapy and support; however, remorse was expressed regarding pandemic circumstances to draw long-awaited attention to multi-organ system and respiratory conditions. Conclusion: Participants expressed concepts warranting infrastructural and scientific attention. This framework reflects pre- and intra-pandemic voiced needs in sarcoidosis and may be an agent of sensitization and strategy for other serious health conditions. A global query into sarcoidosis will be undertaken. with analyses rooted in grounded theory. Recruitment occurred by self-referral through patient advocacy groups. Results: A total of 28 people living with sarcoidosis participated. The majority of patients had multi-system and severe sarcoidosis. Dominant themes were consistent across groups with differences expressed in spirituality and government and health systems. Racial, gender, and able-bodied inequity were voiced regarding healthcare access and intervention, societal interactions, and COVID-19 exposure and contraction. Agreement regarding extreme disruption in care and communication created concern for disability and survival. Concerns of COVID-19 exposure triggering new sarcoidosis cases or exacerbating established sarcoidosis were expressed. Pre-COVID-19 impediments in sarcoidosis healthcare delivery, medical knowledge, and societal burdens were intensified during the pandemic. Conversely, living with sarcoidosis cultivated personal and operational preparedness for navigating the practicalities and uncertainties of the pandemic. Optimism prevailed that knowledge of sarcoidosis, respiratory, and multi-organ diseases could provide pathways for COVID-19-related therapy and support; however, remorse was expressed regarding pandemic circumstances to draw long-awaited attention to multi-organ system and respiratory conditions. Conclusion: Participants expressed concepts warranting infrastructural and scientific attention. This framework reflects pre-and intra-pandemic voiced needs in sarcoidosis and may be an agent of sensitization and strategy for other serious health conditions. A global query into sarcoidosis will be undertaken. Keywords sarcoidosis, patient-centered, multi-system, multi-organ, quality of life, chronic, disparities, COVID During the COVID-19 pandemic, both patients and clinicians experienced extreme challenges in providing and receiving sarcoidosis care. Further, patients with sarcoidosis had a unique experience of living in the COVID-19 pandemic as a vulnerable population. In order to better understand and improve the quality of healthcare delivery and living, we convened a multi-national research team consisting of patient leaders, physicians, nurses, and therapists. We interviewed 28 patients recruited through sarcoidosis patient organizations in the 3 hardest impacted English-speaking cities during the early COVID-19 pandemic: London, New Orleans, and New York. The majority of participants had a multi-organ systems and severe sarcoidosis. A great deal was learned to guide future healthcare delivery, disease management, and education. Among the many concepts expressed by the participants, there was great similarity across the 3 groups. The differences between the groups were in an expression of spirituality as well as in details of government and health systems. Race, gender, and disability (including people with sarcoidosis) were voiced as inequities in healthcare access and intervention, societal respect, as well as disproportional COVID-19 exposure and contraction, with the expressed concern that these groups were at higher risk during the pandemic. There was clear agreement among all groups that there was an extreme disruption in care and communication and great concern that their diagnosis created survival disadvantage because of the disease biology and because they are less likely to receive life-saving treatment. These were thought to be true pre-COVID-19 but became overt during the pandemic. The participants noted many crossover concepts between sarcoidosis and COVID-19. Some concepts related to whether COVID-19 infection could increase sarcoidosis disease activity or trigger new sarcoidosis cases, other concepts related to the biologic similarity of both being systemic multi-organ diseases mostly recognized for lung involvement. Many participants expressed struggles related to future health uncertainty, and lack of health professional knowledge. Another similarity was that having sarcoidosis before the COVID-19 pandemic provided patients with experience to cope with the pandemic better than the general public. Many thought that the experience of people with sarcoidosis could help those living with multi-systemic effects of COVID-19. Sarcoidosis is a systemic disease of granulomatous formation and aggregation in single or multiple organs, conferring a wide spectrum of multiple and diverse manifestations, symptoms, and severity. Disease burden is driven by inflammation which, if not self-limited or pharmacologically quelled, results in progressive, life-threatening damage, and fibrosis. The destructive capacity of sarcoidosis varies depending on the volume of granulomatous burden, organ/s involved, and location. For example, moderate granulomatous burden in cardiac muscle may be "clinically silent," whereas miniscule aggregates crossing conduction pathways can cause fatal arrhythmias. Pulmonary, cutaneous, and ocular involvement are commonly recognized; while cardiac, neurological, gastrointestinal, and osseous manifestations are likely under-reported. Several antigenic triggers are associated with sarcoidosis including mold, infectious and chemical exposures, with yet unknown influence on phenotype, genotypic interactions, or prognosis (1) . The systemic inflammatory nature of active sarcoidosis can cause fever, fatigue/malaise, arthralgia/arthritis, atypical cutaneous, and other diffuse nonspecific manifestations challenging the ability to distinguish between active sarcoidosis and other concomitant diseases. Disease burden, immunosuppressive treatment, infection, and poor access to care worsen health outcomes. COVID-19 is a mild to severe respiratory and multi-system illness transmitted chiefly by infectious respiratory droplets. COVID-19 is commonly characterized by fever, cough, and shortness of breath potentially progressing to respiratory failure. However, both in COVID-19's acute and chronic forms, multiple organ systems may be involved resulting in cutaneous, articular, neurological, cardiac, gastrointestinal, and hematological manifestations. The chronic form may be related to immune activation, long recovery, persistent residual damage to organ tissue as with sarcoidosis. At the time of this publication, the literature lacks an investigation of sarcoidosis as experienced by patients in the COVID-19 pandemic. The stark initial challenges encountered by patients and clinicians in the early COVID-19 pandemic predominantly expressed through international, national, and local online support groups inspired this study. This study examines the experience of living with sarcoidosis in three of the hardest impacted regions during the early COVID-19 pandemic: London, New Orleans, and New York. The impact of the COVID-19 pandemic on people living with sarcoidosis was examined in three global English-speaking areas with the highest COVID-19 incidence and death per capita during April 2020: London, UK; New Orleans, USA; New York City, USA (2, 3) . Three geographically distinct focus groups (FGs) with an a priori decision of 5 to 12 attendees per group based on the response, were conducted in April/May 2020 (Figures 1 and 2) . The study protocol was approved, implemented, and with all participants consented according to Institutional Review Board #743566. Potential participants self-referred to the project after viewing sarcoidosis support group email or social media announcements, and were accepted on a first-come basis. Face-to-face FG interviews via Zoom.us were closed to nonparticipants, planned for 90 to 120 min, led by AMR and LAS with an open interview framework relying upon patientdriven discussion for the content of COVID-19 related topics. FGs began with interviewer and participant introductions. Participants were invited to state their first name, the duration, degree of organ involvement, and treatment of sarcoidosis, along with a history of COVID-19 exposure or infection. Two questions drove the FG discussions: (1) "Thinking back to just before COVID-19 emerged, and then thinking about now, how has COVID-19 impacted your life as a person living with sarcoidosis?" (2) "Thinking back to prior to COVID-19 and then now, how has your healthrelated to sarcoidosis changed since COVID-19 emergence?." During the discussion, intuitive interviewer probes delved for further detail or to check for a collective agreement. FGs were audio-recorded with concomitant field notes and transcribed verbatim. Participants were aware of the interviewers' backgrounds and openly informed of the project's goals and motivations. The study team consisted of 4 experienced qualitative researchers (AMR, DN, KJ, LAS) an RN/PhD and psychometrician, an MSc/PhD and 2 MD/MPHs, and 6 patient research partners (PRPs), a male and female from each geographic area, nationally recognized peer leaders with prior exposure to collaborative research (4) . This resulted in 10 coders for each transcript. PRPs were trained on practical aspects of grounded theory (5, 6) which guided transcript analyses, concept generation, triangulation, theme emergence, and framework production. PRPs' individual and group analyses provided the initial concept generation for each transcript, which was then merged with the iterative in-depth manual and Nvivo10 software-generated analyses by the professional researchers. A sequential nominal group approach facilitated all collective concept generation, agreement, and framework production (7, 8) . PRPs were restricted to observing the initial consensus exercises of their own FG's transcript but responsible for review and feedback on the team's analysis. A total of 28 interviewees (Table 1 ) participated without attrition. The median FG duration of 2.83 h and was driven by patient contributions and enthusiasm. Each FG member received their group's transcript for feedback, without further commentary. Data saturation for each focus group was cross-checked by concept occurrences in the other 2, concept consistency prevailed between groups except in areas of spirituality and regional particulars. No repeat interviews or follow-up questions occurred. Three overarching themes (bold-type) shelter all concept items (Box 1). Major themes (see Supplemental Material), though predominately under one OT, may overlap with another OT. Major themes are described below with selected quotes (Box 2). Divergent themes are addressed under relevant OTs. "Sarcoidosis Survival Ecology" (OT1) defined by its main themes, "Interconnections" and "Personal Evolution and Emergence," reflect themes of multi-faceted, iterative, interdependent actions, and experiential personal growth while living with sarcoidosis describing identity, knowledge, and learned-COVID-19/crisis preparedness. Networks, Activism, and Healing. A clear distinction was made between support groups and focus groups. Both created a sense of "belonging," "support," and "validation," but support groups facilitated bi-directional knowledge sharing, peer mentorship in navigating healthcare, resources, and expectations. Focus groups stimulated pragmatism, relating to research, education, and health systems policy needs for standardized information. Divergence. All participants of the New Orleans group were strongly and normatively declarative in spirituality and faith, which did not occur in other groups. Self-Advocacy and Growth. Participants unanimously confirmed a trajectory of being initially devastated by a sarcoidosis diagnosis and the multi-relational experience of uncertainty and the subsequent gathering of motivation to become knowledgeable about the disease, health systems, and coping. Beyond the fear and dread of COVID-19, there was agreement that wisdom gained from living with sarcoidosis put them in a place of preparedness to protect against COVID-19, such as the early self-imposed implementation of family/self-isolation, and coping with the complex uncertainties associated with COVID-19. Self-advocacy and self-protection were perceived as sometimes creating a hardship on personal and professional relationships during COVID-19. It placed additional work or restrictive burdens on others; including forcing patients to share the seriousness of their health status with others when they would have otherwise elected not to, e.g. employers, visitors, etc. Credible Information. Participants initially were heavily involved with COVID-19-related news several hours daily, and subsequently restricted their exposure to less than an hour to protect psychological and emotional well-being, productivity, and engagement in more fulfilling life activities. Discussions persisted around the credibility of COVID-19 information. Most participants distilled information from several sources; with reliance on scientists from governmental or international organizations such as Centers for Disease Control (CDC) or World Health Organization (WHO) or National Health Service (NHS). Widely expressed was that the presentation of information was misused and misrepresented for political, self-interested gain and by the media for "shock value." "COVID-19-Sarcoidosis Interactions and Similarities" (OT2). addresses the repeated voicings related to the myriad colliding facets between the respiratory and multi-organ system nature of sarcoidosis and of COVID-19; as well as questions regarding the viral triggering of inflammatory diseases. Disease Behaviors. Clinical guidance was confused by similar symptomatology and manifestations between sarcoidosis flaring and COVID-19, i.e. sarcoidosis activity versus COVID-19 infection versus both occuring simultaneously; and made more complicated by COVID-19 testing/ re-testing's questionable utility and reliability. Participants reported having to rely upon clinicians without experience in sarcoidosis to answer complex questions. This included addressing sarcoidosis flares, whether to continue sarcoidosis treatment and confusion over sarcoidosis versus COVID-19 symptoms. Further, in the United Kingdom, this became especially problematic when relying upon GP diagnosis for the attainment of COVID-19 protective status for vulnerable people (9, 10) . These uncertainties led to a lack of confidence in COVID-19 screening, as well as diagnostic interpretations and treatment plans. Additionally confounding was the potential of immunemodulating sarcoidosis medications to increase vulnerability to infection, potentially conferr a protective effect or even be effectice in the treatment of COVID-19. Concern over the potential of potential pathogenic interactions between COVID-19 and sarcoidosis disease behavior, were diffuse in all groups, and notably in those with cardiac sarcoidosis. Despite, interest in sarcoidosis therapies potentially attenuating COVID-19 virility, participants' fear of their immunosuppressed status drove compliance with the new/alternate sarcoidosis treatment strategies in response to the pandemic. Shared and Intersecting Patterns. Evolving knowledge of research, diagnosis, natural history, and disease phenotypes, prognostic factors, and management as well as patient, general population, and clinician education were voiced as sharing similar trajectories in COVID-19 in the general population and the pre-COVID-19 sarcoidosis experience. The groups expressed that respiratory and multi-organ system conditions, like sarcoidosis, historically received limited public awareness, research attention, and funding; and that the COVID-19 pandemic may lead to a greater appreciation of and knowledge in respiratory and multi-organ system diseases. Further expressed was the hope that knowledge gained in sarcoidosis (1, (11) (12) (13) (14) (15) (16) might be useful in understanding the quality-of-life and therapeutic realms of COVID-19 treatment and recovery. Participants had proactive self-determination strategies distilled to minimizing risk, vigilance in detection, paying attention to distinctive features of otherwise non-specific symptoms, for example, fever-type, and pattern, and self-reliance in deciding when and how to seek medical treatment. Though sarcoidosis was perceived as an experience which cultivated skills that facilitated greater ease in coping with and responding to the threat of exposure and to the uncertain medical knowledge during COVID-19; a sarcoidosis diagnosis was perceived as creating disparities when compared with the healthy population impacting "eligibility selection" for life-saving COVID-19 interventions such as mechanical ventilation and ICU admission. Many perceived COVID-19 infection as inexorably linked to death, in sarcoidosis; therefore each group's COVID-19 survivors were important catalysts for expressed new perspectives, relief yet sustained vigilance. Healthcare Logistics. COVID-19-related disruption on all aspects of routine and emergent sarcoidosis-care was diffusely reported in relation to essential and critical diagnostics, infusions, medication assessment/tapering, attainment of refills and communication lines to specialists. Participants expressed a sense Over-Arching Theme 1 (OT1): "Sarcoidosis Survival Ecology" UK-1 "I started shielding in February. I bought my first mask in January. I was in hospital between operations. But it was just my personal previous life experience … I saw it coming." NYC-3 "My son is 15 and he's, being homeschooled again. I did like the fact that he would get up in the morning and go to school every day that would give me time if things really did hurt … as you know, we don't fake being sick we fake being well … so it bothers me that when I'm in a flare he can't be sheltered as much as he normally is." NYC-4 Anyhow, so I try to keep things in perspective. And I've been typing in these comments saying "sarcoidosis" because you know, it is it is a race issue … a lot of African Americans have this disease (sarcoidosis). And I feel like from working in the city … and we were we're all living and functioning within the schools and these buildings that have very poor air quality … UK-3 I took him (her son) out of school probably around the 16th of March. I did not listen to the government. I have an autoimmune disease … NYC-1 I live in an apartment building-a two-floor apartment building. People in my apartment building are going in and out. And I'm terrified to even walk out the front door to check the mail NO-4 last week or so. I had just came from my infusion and stopped at a store and … coughed in the store. When I left … a lady, actually walked up to my car as I was getting in … and she actually sprayed me down with lysol and ran back to her car. Now I'm kind of paranoid because when I go out … although I don't go out much … I'm scared to … cough. NO-1 Disproportionately it's blacks and women on the "frontline" … nurses, hospital workers, grocery check-out is a big one … the people that society relies upon are those types of jobs and … they are at risk for us … of health system abandonment during the pandemic, apprehension was particularly voiced regarding follow-up care by those with cardiac and ocular sarcoidosis and those midstream of a new sarcoidosis diagnositic work-up. These strains led to worry and greater uncertainty for sarcoidosis-related survival. Related to this, participants voiced a sense of guilt in having a health condition that required significant attention and resources, while in the midst of a pandemic. The abrupt discontinuation or prolonged unchecked administration of glucocorticoids, were voiced experiences. Participants reported difficulties with hydroxychloroquine attainment as a result of depleted supplies as well as roadblocks by insurance in the United States. "Environmental/Societal External Needs and Influences" (OT3) captures predominantly fixed situational factors that patients perceive require patient effort to navigate and influences patient behavior and outcomes. It characterizes factors which are predominantly unidirectional pressures. This is different from the bi-directional inter-relational growth experiences of "Sarcoidosis Survival Ecology" (OT1). These external constructs include healthcare system access, de-prioritization of COVID-19 treatment for pre-existing conditions, race, gender and socio-economic status* (SES) (17) as well as having a disability, work options, positive and negative community influences, and one's physical environment. Under these confines managing COVID-19 exposure, caring for other vulnerable people, and relationships are described as operative themes. Gender, Socio-Economic, and Disability Inequity. "Discrimination" and "Healthcare Disparities" were pervasive themes relational to recurrent sub-themes including a disproportion of essential workforce thus increasing COVID-19 exposure and contraction, financial hardship pressuring work and caring for vulnerable others. Also, many sub-themes of deficiency in access to education, computers, technology as well as being pre-disposed to disrespectful social interactions (18) . While racial, gender, and SES health disparities such as COVID-19 testing and insurance coverage were less prominently voiced in the UK group, health disparities related to geographic location and preferential medical resource allocation to the ablebodied without underlying health conditions, such as access to critical care beds or mechanical ventilation, was strongly voiced by all groups. Managing Exposure. Having sarcoidosis, immunosuppression, and prior non-COVID-19 infection experiences drove subthemes of early self-imposed isolation, moving from city dwellings, and combining or splitting households to reduce locationbased risk. Household decision-making regarding decontamination rituals, obtaining and handling of essential supplies, and risk reduction strategies between household members were motivated by the immunosuppressed vulnerability. Social Factors. Positive and negative social factors were voiced. Participants noted that local communities rallied to assist and protect those more vulnerable, but alternatively participants reported feeling increasingly vulnerable due to self-interested individualistic attitudes toward protecting others and because of "guidance" from unreliable sources. Participants also experienced negative attitudes in pre-COVID-19 times for sarcoidosis symptoms such as coughing in public-now markedly exacerbated. In the UK, a "shielding letter" for high or moderate risk groups was necessary for priority food and pharmacy deliveries and to access special protected shopping hours (9,10). However, sarcoidosis was not specifically listed (10, 19) with patients frustrated and reliant on the local physician/ GP for issuance. The practical value of the letter was perceived to have both negative (potentially being denied ventilator support) and positive (priority access to medications and groceries) implications. Work and Family. Patients reported myriad layers of complexity dictated by circumstance influencing work and home relations with resultant physical, financial, logistical, and psychological implications. A number of participants were primary caregivers which had further implications for selfexposure as well as protecting and providing for the In terms of protection and protecting others-historically black lives are less valued in society and health wise … now with this pandemic … UK-2 … the effect it has on families. And that's a two way thing. what we ask from our children and our spouses is extreme because they can't shield with us. it's all going to be down to personal trade-offs over … keeping ourselves safe, keeping our families safe-sending their children to school and so on, but also the trade-off of how we maintain the economic viability of our family units. And all of these are mutually incompatible. NYC-4 I have an elderly father. He's 94 and I'm power of attorney for him and I was trying to do some business for him. I couldn't do it online. And I had to go out on Thursday, and it was so overwhelming. I didn't realize maybe because I've been inside so long. UK-1 But if it was a case of a triage, then … I wouldn't be very high on the list (due to cardiac sarcoidosis). Which is which is fine, it's available resources. UK-2 if I get COVID-19 and have to go to ITU … they're going to say "she's not gonna survive, so she's not going to get an ITU (ICU) bed." vulnerable family member. Configuration of physical space impacted exposure risk, personal relationships, and wellbeing. The UK organized specialty provisions for childcare and eldercare for essential workers as well as work accommodations for vulnerable employees or employees with vulnerable family members at home. In the best of times, it is challenging for clinicians and patients to address healthcare needs related to complex multi-organ system diseases such as sarcoidosis. As researchers, investigating sarcoidosis experiences of the COVID-19 pandemic, the purview of the sarcoidosis experience before the COVID-19 pandemic provided an essential relational platform. The COVID-19 pandemic has amplified and disclosed underlying infrastructural vulnerabilities that had routinely impacted this population, but it also appears to have underscored strengths often cultivated by living with a serious health condition. This research exemplifies the extent to which patient expertise has the potential to drive research and health system priorities. As a result of living through the COVID-19 pandemic, people with complex health conditions can provide guidance on both how navigate the extreme times precipitated by a pandemic as well as how this experience can influence routine healthcare delivery in the future. We anticipate these pre-and intra-pandemic findings are unlikely to be unique to sarcoidosis (19) and ardently hope that this dense, intense base of information will inform investigational off-shoots into psychological, systems management, and quality-of-life research in sarcoidosis and other multi-system diseases-including "post-COVID-19 syndrome." The framework is intricate and more extensive than could have been anticipated, but it captures the necessary detail reflective of a complicated multi-system disease (sarcoidosis) experienced with in the context of another biologically and socially complex disease . In this regard, the framework is an agent of sensitization and strategy that can be tested and applied beyond sarcoidosis. In regard to sarcoidosis, the framework discloses unstable underpinnings to healthcare system structure, education, communication, and service industries that required the push of a crisis for overt revelation. The crisis also illuminated pre-existing education and knowledge gaps, and the need to be better equipped to support those living with precarious multi-system diseases in a crisis. Importantly, the pandemic heightened participants' pre-existing sensibilities and frustrations regarding inequities of disability and race, and healthcare structure and society interactions as a subclass, particularly in relation to research funding, allocation of healthcare resources, knowledge, and clear communication. The strengths of the design harnessed the perspectives, priorities, and concerns of participants residing in global English-speaking areas with the highest incidence and mortality during the time of data collection. Thus, we anticipate that the broadest and most intense experiences of the COVID-19 outbreak as experienced by people living with sarcoidosis are captured here. The collection time-period occurred after the initial few weeks of isolation measures, therefore, allowing for valuable assimilation perspectives and experiences to augment relevant concept collection. In this study, patient participants, PRPs, and researchers developed an authentic collaboration at the onset, in question framing, research design and conduct, and subsequent dissemination strategies. Power-sharing served to reduce inequalities and enabled honest and transparent discussions. Pervasive in all groups was the need for improved access to specialist physicians and nurses for a deeper lever of individualized support and care. The authors draw attention to the lack of any patient and caregiver inclusion on COVID-19 related research published to date. These frustrations were recently expressed by the physician-patients with COVID-19 (20) and echo throughout our findings with relevance to the COVID-19 or sarcoidosis disease experience or both combined. These physician-patients urge the formation of "one-stop" clinics as hubs of care, pattern-recognition and sentinel expertise to identify and manage COVID-19 sequelae in order to expeditiously augment and propel the acquisition and dissemination of medical knowledge. Sarcoidosis centers of excellence still appear to have a sequestered recognition and treatment knowledge not yet deployed in general pulmonary, rheumatology, or other sub-specialty clinics, as reflected in the framework. However, the framework also states that the global experience of COVID-19 may yet influence the frontiers of knowledge dissemination in these rarer complex multi-system diseases. Whether underlying inflammatory diseases are pathogenically triggered or worsened by the contraction of COVID-19 was presented in this data months before such suppositions were published in the literature (21, 22) . This speaks to seasoned patients' instinctual inclination related to sarcoidosis natural history, susceptibility according to the degree of immunosuppression, and conceivable synergistic and potentiating pathogenicity. Similarly, astute speculations regarding vaccine availability, effect, and management-as well as discriminatory implications of COVID-19-again, seemed driven by patients' expertise acquired by experiential sensitization to pathogenicity and medical knowledge exposure. Regarding study limitations, the hope for survival appears to drive content, however, defeat, a fairly common concept expressed on patient social media, is absent in our study. Selection bias with participant self-referral via patient associations may have attracted participants: (a) with higher levels of self-efficacy skills, (b) "seasoned" with longer disease durations and possibly "upskilled" in coping, and (c) less likely hampered by psychological demotivation. Outreach strategies designed specifically to support those newly diagnosed and experiencing mental hardship could be warranted. We regret that access to linguistic resources impeded the ability to investigate non-English speaking, high COVID-19 endemic areas. We also recognize that representation was heavily weighted by participants with more severe disease. However, a bias toward disease severity likely intensifies and broadens the conceptual spectrum that might be experienced across sarcoidosis severity and phenotypical differences. We will further examine these differences in the global open-query phase of this project. The conclusions reached in this study promise helpful and generalizable insights; despite constantly evolving information and issues of the COVID-19 pandemic. Data collection was completed prior to the current global concerns of schooling during the pandemic, however the six PRP authors as international leaders advocate this to be a serious situation and best left to parental households to decide on an individual family basis. Future directions are currently querying these results in the global sarcoidosis patient community to assess generalizability and deficits of these findings. Adam Russell supports clinical research on patient experiences of interstitial lung diseases through audio transcription, proof reading, and editing. Adam is primarily a graphic designer, illustrator, and photographer working on a range of eco and ethical projects. Commissioned work includes producing graphics for health-related projects, advertising for vegan products, print and pattern designs, and photographic cataloguing of artistic images and products. Isabelle Lian recently graduated from Tulane University with a Bachelor of Science in Neuroscience and is preparing to enter medical school this summer. Her prior research explored the potential to foster resilient physicians through Compassion Cultivation Training and other mindfulness techniques. In her other patient-centered projects, Lian has a special interest in the areas of COVID-19, diet, and exercise. She is examining the impact of these on the patient experience in conditions such as sarcoidosis, scleroderma, and myositis. Matthew R. Lammi is a pulmonary and critical care physicianresearcher who focuses on patients with pulmonary hypertension, connective tissue disease-related pulmonary complications, and sarcoidosis. He is the Director of the Comprehensive Pulmonary Hypertension Center-University Medical Center and a member of the New Orleans Scleroderma and Sarcoidosis Patient Care and Research Center. His research is focused on early identification of pulmonary hypertension and predictive modeling. Mary B. Scholand is an Associate Professor of Medicine at the University of Utah and is the Director of the Interstitial Lung Disease Program. She has focused her practice on improving the care and quality of life for patients with all interstitial lung diseases including sarcoidosis. She is active in many multicenter clinical networks. Her research includes characterizing ILD phenotypes, conducting therapeutic clinical trials and patient-reported disease characterization. Anne-Marie Russell is a senior lecturer and research lead in the College of Medicine and Health, University of Exeter. She maintains clinical activities through honorary appointments with Royal Devon and Exeter and Imperial College Healthcare NHS Trusts. Anne-Marie's research is focused on patient reported measures including experience, engagement and health outcomes employing mixed methods and patient-centred approaches. Anne-Marie collaborates on studies relating to interstitial lung disease (ILD) and palliative care. She is the author/co-author of numerous peer-reviewed publications and regularly conducts peer review. Anne-Marie works collaboratively with ILD and sarcoidosis charities in the UK, US and Europe. Centers for Disease Control Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups Grounded theory methodology: an overview Qualitative methods to advance care, diagnosis, and therapy in rheumatic diseases Multiple articles and chapters in PDF format by the RAND Organization The effectiveness of nominal, Delphi, and interacting group decision making processes The burden of neurosarcoidosis: essential approaches to early diagnosis and treatment Feasibility, utility and symptom impact of modified mindfulness training in sarcoidosis Sarcoidosis and work participation: the need to develop a disease-specific core set for assessment of work ability Management of extrapulmonary sarcoidosis: challenges and solutions Clinical phenotyping: role in treatment decisions in sarcoidosis Physical activity and training in sarcoidosis: review and experience-based recommendations Caste: The Origins of Our Discontents Experiences of patients With rheumatic diseases in the United States during early days of Sarcoidosis UK, Sarcoidosis Awareness Foundation of Louisiana, National Sarcoidosis Support Network, New Orleans Sarcoidosis Support Group. AMR is a National Institute for Health Research (NIHR) Senior Nurse and Midwife Research Leader. The views expressed in this article are those of the author(s) and not necessarily those of the NIHR, or the Department of Health and Social Care. The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The study protocol was approved, implemented, and with all participants providing consent according to Institutional Review Board #743566 and the World Medical Association Declaration of Helsinki. This study did not involve animals. Lesley Ann Saketkoo https://orcid.org/0000-0002-1878-8591 Supplemental material for this article is available online. He is heartened that patient voice and expertise is increasingly recognized as integral to science and policy-making.